FEFU Int. Admission Office:
+7 (423) 265 24 24
A group of researchers of the Far Eastern Federal University starts pre-clinical trials of a new medication developed to cure Alzheimer’s disease. This work is supported by the Special Federal Program and is carried out in cooperation with the Research Institute of Chemical Diversity of the ChemRar Center for High Technologies, a world leader in the field of drug development. By late 2016, the scientists expect to receive a pill prototype that would be ready for clinical trials on humans.
FEFU researchers have managed to develop a unique substance whose structure is not disclosed yet, but it is already a known fact that similar substances are being used to treat cardiovascular diseases to reduce clotting thrombogenesis.
FEFU scholars have discovered that this substance encourages decomposition of amyloid plaques in the brain as one of the hypotheses states that accumulation of the beta-amyloid is the reason of Alzheimer’s disease, and accumulation of the plaques leads to impairment of memory, attention and other cognitive abilities. After completing lab studies on animals and cell structures, the scientists have received data that the amount of amyloid actually decreases, which gives hope that this medication would be able to improve the lives of the patients with Alzheimer’s.